Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 654 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line... June 7, 2023 FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy September 5, 2024 The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce September 27, 2018 Incidence of Colorectal, Breast, Kidney, Pancreatic, and Uterine Cancers is Increasing... May 18, 2022 Load more HOT NEWS Distinct and Overlapping Pathways Contribute to the Efficacy of Nivolumab-Based Regimens... EMA Recommends Extension of Indications for Tislelizumab to First-Line Treatment of... ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to... ESMO World Congress on Gastrointestinal Cancer 2022 Barcelona, Spain 29 June...
